A Review of the Management of Gastric Acid-Related Diseases: Focus on Rabeprazole

Clinical Medicine Insights: Gastroenterology

Review

Osamu Kawamura¹  Motoyasu Kusano¹  Shikou Kuribayashi¹  Yasuyuki Shimoyama¹  Atsuto Nagoshi¹  Masatomo Mori¹  Hiroko Hosaka¹  Hiroaki Zai¹ 

[1] Department of Endoscopy and Endoscopic Surgery, Gunma University Hospital, 3-39-15 Showamachi, Maebashi Gunma 371-8511, Japan.;

关键词: acid-related diseases;    CYP2C19;    FSSG;    functional dyspepsia;    NERD;    rabeprazole;   

DOI  :  10.4137/CGast.S5133

来源: Sage Journals

【 摘 要 】

Current treatment guidelines for acid-related diseases (ARDs) recommend first-line treatment with a proton pump inhibitor (PPI) to reduce gastric acid production. PPIs are indicated in the management of gastroesophageal reflux disease (reflux esophagitis, nonerosive reflux disease), peptic ulcer (gastric and duodenal ulcer, non-steroidal anti-inflammatory drug (NSAID)-associated ulcer, bleeding ulcer), functional dyspepsia, and in association with Helicobacter pylori eradication therapy when needed. Currently, PPIs (omeprazole, lansoprazole, pantoprazole, rabeprazole and esomeprazole) are widely used for the treatment of ARDs. All 5 PPIs are effective. However, there are differences in PPI pharmacokinetic and pharmacodynamic profiles that might influence their clinical utility. Rabeprazole is a useful option for the treatment of acid-related diseases due to its rapid onset of acid inhibition and few drug interactions.

【 授权许可】

CC BY-NC   
© 2011 SAGE Publications.

【 图 表 】

Figure 1.

Figure 7.

Figure 3

Figure 1